This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase I trial of the combination of oxaliplatin and PS-341 (an inhibitor of ubiquitin-proteasome degradation of p53, IkB, and other cell-cycle regulatory proteins) in the treatment of advanced cancer. The goal is to determine the minimal dose requirements for phase II trials and to determine the toxicities of this combination of agents. Patients will be treated as outpatients and will receive infusions of accelerating doses of PS-341 prior to an infusion of oxaliplatin. Endpoints are the identification of a recommended phase II dose of PS-341 and determination of dose-limiting toxicity. 15-30 patients with advanced cancer, good organ function and lack of prior exposure to certain types of agents (thalidomide, cytoskeleton-active agents) will be enrolled, and participation will involve 26 visits for infusions over 3-6 months. The investigators continue to enroll subjects on this study. No data are available as of yet.
Showing the most recent 10 out of 470 publications
